Listen

Press releases

Receive e-mail alerts

Internal link ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
December 08, 2023 at 12:30 PM UTC
Internal link ProQR Announces Third Quarter 2023 Operating and Financial Results
November 07, 2023 at 12:00 PM UTC
Internal link ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing
November 06, 2023 at 12:00 PM UTC
Internal link ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference
September 28, 2023 at 12:00 PM UTC
Internal link ProQR Therapeutics Provides Update on Ophthalmic Assets
September 27, 2023 at 11:00 AM UTC
Internal link ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference
September 07, 2023 at 12:00 PM UTC
Internal link ProQR Announces Second Quarter 2023 Operating and Financial Results
August 03, 2023 at 11:00 AM UTC
Internal link ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets
August 01, 2023 at 11:00 AM UTC
Internal link ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit
July 06, 2023 at 11:00 AM UTC
Internal link ProQR Announces First Quarter 2023 Operating and Financial Results
May 16, 2023 at 11:00 AM UTC
Internal link ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023
May 09, 2023 at 12:00 PM UTC
Internal link ProQR Announces Upcoming Investor Conferences in April and May
April 20, 2023 at 12:00 PM UTC
Internal link ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023
April 18, 2023 at 12:00 PM UTC
Internal link ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event
March 29, 2023 at 12:00 PM UTC
Internal link ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing
March 14, 2023 at 12:00 PM UTC
Internal link ProQR to Present at Upcoming Scientific and Industry Conferences
March 07, 2023 at 01:00 PM UTC
Internal link ProQR Therapeutics to Host Virtual R&D Event on March 29, 2023
February 28, 2023 at 01:00 PM UTC
Internal link ProQR Announces Results for the Third Quarter of 2016
November 14, 2016 at 12:00 PM UTC
Internal link ProQR Announces that QR-010 Meets the Primary Endpoint in a Proof of Concept Study of Homozygous F508del Cystic Fibrosis Patients
October 27, 2016 at 11:00 AM UTC
Internal link ProQR Announces Clinical Data Presentations and Investor & Analyst Event at NACFC
September 27, 2016 at 11:00 AM UTC
Internal link ProQR to Present at Scientific and Investor Conferences in September
September 06, 2016 at 11:00 AM UTC
Internal link ProQR Announces Results for the Second Quarter of 2016
August 17, 2016 at 11:00 AM UTC
Internal link ProQR Receives Fast Track Designation from FDA for QR-010 for Cystic Fibrosis
July 19, 2016 at 11:00 AM UTC
Internal link ProQR to Release Topline Data from Proof of Concept Study of QR-010 in Cystic Fibrosis Patients at NACFC
June 21, 2016 at 01:00 PM UTC
Internal link ProQR’s Drug Candidate QR-110 for Leber’s Congenital Amaurosis Type 10 Receives EMA and FDA Orphan Drug Designation
June 01, 2016 at 11:00 AM UTC

Press releases

Internal link ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets

Internal link ProQR Announces Third Quarter 2023 Operating and Financial Results

Internal link ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing

Internal link ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference

Internal link ProQR Therapeutics Provides Update on Ophthalmic Assets

Internal link ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference

Internal link ProQR Announces Second Quarter 2023 Operating and Financial Results

Internal link ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets

Internal link ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit

Internal link ProQR Announces First Quarter 2023 Operating and Financial Results

Internal link ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023

Internal link ProQR Announces Upcoming Investor Conferences in April and May

Internal link ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023

Internal link ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event

Internal link ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing

Internal link ProQR to Present at Upcoming Scientific and Industry Conferences

Internal link ProQR Therapeutics to Host Virtual R&D Event on March 29, 2023

Internal link ProQR Announces Results for the Third Quarter of 2016

Internal link ProQR Announces that QR-010 Meets the Primary Endpoint in a Proof of Concept Study of Homozygous F508del Cystic Fibrosis Patients

Internal link ProQR Announces Clinical Data Presentations and Investor & Analyst Event at NACFC

Internal link ProQR to Present at Scientific and Investor Conferences in September

Internal link ProQR Announces Results for the Second Quarter of 2016

Internal link ProQR Receives Fast Track Designation from FDA for QR-010 for Cystic Fibrosis

Internal link ProQR to Release Topline Data from Proof of Concept Study of QR-010 in Cystic Fibrosis Patients at NACFC

Internal link ProQR’s Drug Candidate QR-110 for Leber’s Congenital Amaurosis Type 10 Receives EMA and FDA Orphan Drug Designation